Remicade is given by a healthcare professional as an intravenous (IV) infusion (an injection into your vein given over a period of time). An interaction can occur because one substance causes ...

Expert Rev Clin Immunol. 2010;6(1):9-19. In a large study with a total of 165 consecutive patients who received 479 infliximab infusions, [111] the overall incidence of infusion reactions was ...

Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...

Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...

Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima ® SC’, which was ...